Amorsa is developing a pipeline of products for diseases of the nervous system with our lead candidates initially targeting treatment-resistant depression and moderate-to-severe pain. We also have a discovery screening program underway to identify additional candidates and explore other related indications including post-traumatic stress disorder, bipolar depression, Rett syndrome and obsessive-compulsive disorder.
The World Health Organization estimates that 350 million people are affected by depression worldwide. For as many as 30-40% of patients, depression continues despite multiple courses of treatment. As a result, treatment-resistant depression is an enormous unmet medical need for millions of patients. Amorsa is developing compounds that work through a novel mechanism of action underlying the antidepressant properties of ketamine and its metabolites.
Opioid medications have been used for centuries as the standard of care for moderate-to-severe pain conditions. Opioids are among the most widely prescribed treatment for acute and chronic pain despite significant adverse effects including constipation, respiratory depression, hypotension, nausea and vomiting. There is growing international concern about the devastating life-threatening side effects of opioids and the epidemic the world is facing involving opioid-drug related overdoses, death and dependence. Our lead product candidate, a potent non-opioid analgesic, has been designed to safely treat moderate-to-severe pain and has the potential to help curb the devastating impact of the prescription opioid epidemic.